PL EN


Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
Czasopismo
2015 | 2 | 1 |
Tytuł artykułu

Molecular Genetic Testing in Pain and Addiction: Facts, Fiction and Clinical Utility

Treść / Zawartość
Warianty tytułu
Języki publikacji
EN
Abstrakty
EN
The Brain Reward Cascade (BRC) is an interaction of neurotransmitters and their respective genes to control the amount of dopamine released within the brain. Any variations within this pathway, whether genetic or environmental (epigenetic), may result in addictive behaviors as well as altered pain tolerance. While there are many studies claiming a genetic association with addiction and other behavioral infractions, defined as Reward Deficiency Syndrome (RDS), not all are scientifically accurate and in some case just wrong. Albeit our bias, we discuss herein the facts and fictions behind molecular genetic testing in RDS (including pain and addiction) and the significance behind the development of the Genetic Addiction Risk Score (GARSPREDX™), the first test to accurately predict one’s genetic risk for RDS.
Wydawca

Czasopismo
Rocznik
Tom
2
Numer
1
Opis fizyczny
Daty
online
2015-08-28
Bibliografia
  • [1] Grandy DK, Litt M, Allen L, Bunzow JR, Marchionni M, MakamH, Reed L, Magenis RE, Civelli O: The human dopamine D2receptor gene is located on chromosome 11 at q22-q23 andidentifies a TaqI RFLP. Am J Hum Genet 1989, 45(5): 778-785.
  • [2] Blum K, Noble EP, Sheridan PJ, Montgomery A, Ritchie T,Jagadeeswaran P, Nogami H, Briggs AH, Cohn JB: Allelicassociation of human dopamine D2 receptor gene inalcoholism. JAMA 1990, 263(15): 2055-2060.
  • [3] Conneally PM: Association between the D2 dopamine receptorgene and alcoholism. A continuing controversy. Arch GenPsychiatry 1991, 48(8): 757-759.
  • [4] Clarke TK, Weiss AR, Ferarro TN, Kampman KM, Dackis CA,Pettinati HM, O’Brien CP, Oslin DW, Lohoff FW, Berrettini WH:The dopamine receptor D2 (DRD2) SNP rs1076560 is associatedwith opioid addiction. Ann Hum Genet 2014, 78(1): 33-39.
  • [5] David SP, Strong DR, Munafò MR, Brown RA, Lloyd-RichardsonEE, Wileyto PE, Evins EA, Shields PG, Lerman C, Niaura R:Bupropion efficacy for smoking cessation is influenced by theDRD2 Taq1A polymorphism: analysis of pooled data from twoclinical trials. Nicotine Tob Res 2007, 9(12): 1251-1257.
  • [6] Lerman C, Shields PG, Wileyto EP, Audrain J, Hawk LH Jr, PintoA, Kucharski S, Krishnan S, Niaura R, Epstein LH: Effects ofdopamine transporter and receptor polymorphisms on smokingcessation in a bupropion clinical trial. Health Psychol 2003,22(5): 541-548.
  • [7] Perkins KA, Lerman C, Grottenthaler A, Ciccocioppo MM,Milanak M, Conklin CA, Bergen AW, Benowitz NL: Dopamine andopioid gene variants are associated with increased smokingreward and reinforcement owing to negative mood. BehavPharmacol 2008, 19(5-6): 641-649.
  • [8] Evans DE, Park JY, Maxfield N, Drobes DJ: Neurocognitivevariation in smoking behavior and withdrawal: genetic andaffective moderators. Genes Brain Behav 2009, 8(1): 86-96.
  • [9] Ohmoto M, Takahashi T, Kubota Y, Kobayashi S, Mitsumoto Y:Genetic influence of dopamine receptor, dopamine transporter,and nicotine metabolism on smoking cessation and nicotinedependence in a Japanese population. BMC Genet 2014, 15(1):151.
  • [10] Gilbert DG, Zuo Y, Rabinovich NE, Riise H, NeedhamR, Huggenvik JI: Neurotransmission-related geneticpolymorphisms, negative affectivity traits, and gender predicttobacco abstinence symptoms across 44 days with and withoutnicotine patch. J Abnorm Psychol 2009, 118(2): 322-334.
  • [11] Spitz MR, Shi H, Yang F, Hudmon KS, Jiang H, ChamberlainRM, Amos CI, Wan Y, Cinciripini P, Hong WK, Wu X: Casecontrolstudy of the D2 dopamine receptor gene and smoking status inlung cancer patients. J Natl Cancer Inst 1998, 90(5): 358-363.
  • [12] Reynolds LM, Engin E, Tantillo G, Lau HM, Muschamp JW,Carlezon WA Jr, Rudolph U: Differential roles of GABA(A)receptor subtypes in benzodiazepine-induced enhancementof brain-stimulation reward. Neuropsychopharmacology 2012,37(11): 2531-2540.
  • [13] Blum K, Sheridan PJ, Wood RC, Braverman ER, Chen TJ, Cull JG,Comings DE: The D2 dopamine receptor gene as a determinantof reward deficiency syndrome. J R Soc Med 1996, 89(7):396-400.
  • [14] Blum K, Wood RC, Braverman ER, Chen TJ, Sheridan PJ: The D2dopamine receptor gene as a predictor of compulsive disease:Bayes’ theorem. Funct Neurol 1995, 10(1): 37-44.
  • [15] Blum K, Oscar-Berman M, Demetrovics Z, Barh D, Gold MS:Genetic Addiction Risk Score (GARS): molecular neurogeneticsevidence for predisposition to Reward Deficiency Syndrome(RDS). Mol Neurobiol 2014, 50(3): 765-796.
  • [16] Palmer RH, Brick L, Nugent NR, Bidwell LC, McGeary JE, KnopikVS, Keller MC: Examining the role of common genetic variantson alcohol, tobacco, cannabis and illicit drug dependence: genetics of vulnerability to drug dependence.Addiction 2015,110(3): 530-537.
  • [17] Ducci F, Goldman D: The genetic basis of addictivedisorders. Psychiatr Clin North Am 2012, 35(2): 495-519.
  • [18] Blum K, Febo M, McLaughlin T, Cronjé FJ, Han D, Gold MS:Hatching the behavioral addiction egg: Reward DeficiencySolution System (RDSS)™ as a function of dopaminergicneurogenetics and brain functional connectivity linking alladdictions under a common rubric. J Behav Addict 2014, 3(3):149-156.
  • [19] Moeller SJ, Parvaz MA, Shumay E, Beebe-Wang N, KonovaAB, Alia-Klein N, Volkow ND, Goldstein RZ: Gene x abstinenceeffects on drug cue reactivity in addiction: multimodalevidence. J Neurosci 2013, 33(24): 10027-10036.
  • [20] Blum K, Oscar-Berman M, Jacobs W, McLaughlin T, Gold MS.Buprenorphine Response as a Function of NeurogeneticPolymorphic Antecedents: Can Dopamine Genes Affect ClinicalOutcomes in Reward Deficiency Syndrome (RDS)? J Addict ResTher. 2014:5.
  • [21] Blum K, Kozlowski GP: Ethanol and Neuromodulator influences.A cascade model of reward. In: Ollat H, Parvez S, Parvez H(eds). Alcohol and Behaviour: Basic and Clinical AspectsProgress in Alcohol Research. VSP International SciencePublishers, Utrecht, Netherlands, 1990:131-150.
  • [22] Zhang Y, Gong J, Xie C, Ye EM, Jin X, Song H, Yang Z, Shao Y:Alterations in brain connectivity in three sub-regions of theanterior cingulate cortex in heroin-dependent individuals:Evidence from resting state fMRI. Neuroscience 2015, 284:998-1010.
  • [23] Blum K, Liu Y, Wang W, Wang Y, Zhang Y, Oscar-Berman M,Smolen A, Febo M, Han D, Simpatico T, Cronjé FJ, DemetrovicsZ, Gold MS: rsfMRI effects of KB220ZTM on neuralpathways in reward circuitry of abstinent genotyped heroinaddicts. Postgrad Med 2015, 127(2): 232-241.
  • [24] Levey DF, Le-Niculescu H, Frank J, Ayalew M, Jain N, Kirlin B,Learman R, Winiger E, Rodd Z, Shekhar A, Schork N, Kiefer F,Wodarz N, Müller-Myhsok B, dahmen N, GESGA Consortium,Nöthen M, Sherva R, Farrer L, Smith AH, Kranzler HR,Rietschel M, Gelernter J, Niculescu AB: Genetic risk predictionand neurobiological understanding of alcoholism. TranslPsychiatry 2014, 4: e391.
  • [25] Farris SP, Arasappan D, Hunicke-Smith S, Harris RA, MayfieldRD: Transcriptome organization for chronic alcohol abuse inhuman brain. Mol Psychiatry. 2014.
  • [26] Yan J, Aliev F, Webb BT, Kendler KS, Williamson VS, EdenbergHJ, Agrawal A, Kos MZ, Almasy L, Nurnberger JL Jr, SchuckitMA, Kramer JR, Rice JP, Kuperman S, Goate AM, Tischfield JA,Porjesz B, Dick DM: Using genetic information from candidategene and genome-wide association studies in risk predictionfor alcohol dependence. Addict Biol 2014, 19(4): 708-721.
  • [27] Goldman D: Candidate genes in alcoholism. Clin Neurosci 1995,3(2): 174-181.
  • [28] Chen TJ, Blum K, Mathews D, Fisher L, Schnautz N, BravermanER, Schoolfield J, Downs BW, Comings DE: Are dopaminergicgenes involved in a predisposition to pathological aggression?Hypothesizing the importance of “super normal controls”in psychiatricgenetic research of complex behavioraldisorders. MedHypotheses 2005, 65(4): 703-707.
  • [29] Neiswanger K, Kaplan BB, Hill SY: What can the DRD2/alcoholism story teach us about association studies inpsychiatric genetics? Am J Med Genet 1995, 60(4): 272-275.
  • [30] Mayer P, Höllt V: Pharmacogenetics of opioid receptors andaddiction. Pharmacogenet Genomics 2006, 16(1): 1-7.
  • [31] Butler SF, McNaughton EC, Black RA: Tapentadol abusepotential: a postmarketing evaluation using a sample ofindividuals evaluated for substance abuse treatment. PainMed 2015, 16(1): 119-130.
  • [32] Jannetto PJ, Bratanow NC: Pain management in the 21stcentury: utilization of pharmacogenomics and therapeutic drugmonitoring. Expert Opin Drug Metab Toxicol 2011, 7(6): 745-752.
Typ dokumentu
Bibliografia
Identyfikatory
Identyfikator YADDA
bwmeta1.element.-psjd-doi-10_1515_addge-2015-0001
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.